The Ebola virus disease outbreak that swept Guinea, Liberia and Sierra Leone in 2014 reminded the world of the dangers of diseases transferred from animal reservoirs, or zoonoses (Curr. Biol. (2014) 24, R1139-R1141). They tend to be deadlier than diseases adapted to the human host, and, once they establish a transmission chain between humans, it can become very hard to stop them. The West African Ebola epidemic became the largest of its kind by May 2014, and two years later the World Health Organisation estimated the total death toll as being 11,310, out of 28,616 reported cases.
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As the epidemic unfolded, treatment of the symptoms, such as rehydration therapy, helped to reduce the mortality rate, initially reported to be above 70%, to below 50%, while systematic control of transmission routes, including infection during patient care and at funerals, eventually enabled the countries affected to end the outbreak. Since then, only one small outbreak was reported, which killed four people in the Democratic Republic of the Congo between April and July 2017.
However, the deadly threat remains, as the disease is still poorly understood, there is still no cure, and vaccines are still in experimental stages and can only be used as a last resort in situations of acute danger. Research is slowly catching up with the disease that may come back to haunt us at any time.
Virus structure
As Ebola was quite rare prior to the 2014-2015 epidemic and any work involving the live virus requires the highest security level, scientifi c knowledge about it still has some signifi cant gaps right down to the molecular level. Moreover, there are only a few closely related viruses to which we can draw comparisons. The genus Ebolavirus comprises fi ve known species, four of which have caused Ebola virus disease in humans. Their closest relative is the Marburg virus (genus Marburgvirus), which has only caused a few outbreaks and is mainly of concern as a potential agent in bioweapons. Both genera belong to the family of fi loviruses (Filoviridae), which also includes the genus Cuevavirus.
Recent progress in structural research also highlighted how much remains still unknown about these viruses. Researchers at the University of Marburg, Germany -in the town where the eponymous fi lovirus was discovered at Behringwerke in 1967 -have now presented a detailed model of the capsid structure of Ebola virus, using cryo-electron microscopy of a capsid built from truncated monomers in combination with a crystallographic structure of the monomer in isolation. The capsid is a hollow tube built as a helical assembly of protein monomers. It is around 80 nanometres in diameter and can grow to lengths of more than one micrometre producing the characteristic elongated fi brils visible in light microscopy.
Unlike the classical cylindrical structure of the tobacco mosaic virus (TMV), where the protein capsid assembles around the RNA, the genome of the much larger fi loviruses appears to be stored in a cleft running along the outside of the cylindrical core structure, following the helical arrangement of the protein monomers.
The groups of John Briggs at EMBL Heidelberg and Stephan Becker at the University of Marburg built a simplifi ed capsid cylinder from the truncated monomer containing only the fi rst 450 amino acids of the 738-residue protein.
Whereas the full-length protein requires the participation of two further, smaller proteins -VP25 and VP35 -for
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Current Biology 28, R51-R65, January 22, 2018 its assembly, the fragment used assembles readily on its own. The likely explanation of this difference lies in the intrinsically disordered state of the discarded carboxy-terminal fragment, which presumably binds to the smaller proteins in the intact virus, but in their absence inhibits an orderly assembly.
Based on their new 6.6 Å (0.66 nm) structure of the simplifi ed capsid, Briggs and Becker could gain new insights into the mechanisms of the RNA-protein interactions in the intact virus. Previously, researchers had assumed that the cleft seen in the crystal structure of the monomer closes around the RNA. Modelling the intact virus on the basis of the new structure, however, suggests that the cleft remains open and the RNA is protected by a protein helix that reaches across the cleft. This helix had not been recognised previously, as the relevant sequence is disordered in the monomer. These fi ndings once more underline the importance of intrinsic disorder in protein structure for biological functions, including many of medical relevance.
The structural and mechanistic details of the two smaller proteins, which so far only appear as bulges on the low-resolution structures of the intact viruses, are among the many details still left to clarify. A better understanding of the mechanistic details of these viruses could yet lead to unexpected ways of treating the disease.
Treatments and vaccines
Until now, there has been no known treatment for any disease caused by fi loviruses, apart from the straightforward and sometimes life-saving alleviation of dangerous symptoms such as dehydration. Only a few leads towards possible treatments have emerged so far. As clinical trials for effi ciency are impossible with such dangerous and normally rare diseases, a few potential treatments were tested during the West African epidemic on the basis of animal results alone. None of them demonstrated unequivocal treatment success in the limited time while infected patients were available.
Blood transfusions from Ebola survivors have in some cases been used successfully and are backed by the WHO, which has issued preliminary guidelines for their use.
Most recently, Jakob Nilsson from the University of Copenhagen, Denmark, together with Stephan Becker's group in Marburg, identifi ed a new host factor necessary for the spread of an Ebola virus infection. Working with cultures of human cells, Nilsson and colleagues demonstrated that Ebola propagation recruits the human phosphatase enzyme PP2A-B56 to activate its own VP30 protein, the unphosphorylated version of which is necessary for transcription. (Mol. Cell (2018) DOI: https://doi.org/10.1016/j. molcel.2017.11.034). Using a specifi c inhibitor of this phosphatase, the researchers could inhibit the transcription and spread of the virus, reducing it tenfold.
A few vaccine candidates existed at the time of the West African epidemic. The candidate VSV-EBOV, based on the vesicular stomatitis virus in combination with an Ebola-typical glycoprotein, was used experimentally in Guinea during the epidemic, and a study published at the end of 2016 reported it to be highly effective in protecting against the disease (Lancet (2017) 389, 505-518).
Following a carefully designed ring immunisation scheme, more than 4,000 contacts as well as contacts of contacts of patients confi rmed to be infected with Ebola were identifi ed and considered for vaccination. Those who were eligible and gave consent were randomly assigned to either immediate vaccination or vaccination after a delay of 21 days. None of the contacts vaccinated immediately contracted the disease, while in the delayed control group of around 2,000 people, 23 cases of Ebola arose.
After advice from an independent safety board, randomisation was then abandoned and immediate vaccination offered to all eligible candidates identifi ed in the contact rings around known cases. Overall, 5,837 individuals were vaccinated, of whom none was diagnosed with Ebola more than 10 days after immunisation. Three patients suffered serious side effects but all recovered without lasting harm. Thus, VSV-EBOV can count as the fi rst effi cient vaccine against Ebola virus disease and may become useful in similar ring vaccination responses in future epidemics.
In May 2017, WHO director general Margaret Chan met political leaders from the West African nations struck by the epidemic at a summit in Guinea, where the ring vaccination trial was held. She praised the success of the trial as the best news of the year 2016 and said that, because of it, "the world is far better prepared for another Ebola outbreak." She also highlighted possible spill-over benefi ts, which imply that the Current Biology 28, R51-R65, January 22, 2018 R53 successful strategy could be copied in the fi ght against other diseases in the situation of a dangerous epidemic.
Immunisations are a highly effi cient tool to rein in and even eradicate a known pathogen that is established in the human population. However, as the repeated worries around fl u vaccines and the threats of new variants of avian infl uenza have shown, they have their limitations when dealing with zoonoses, as one never knows which variant of a pathogen might jump across the species barrier next. To limit the dangers, a better understanding of the ecological context is necessary.
Reservoir bats
While the specifi c animal source of the recent Ebola epidemic remains unknown, there are known natural reservoirs and transmission paths. Fruit bats (family Pteropodidae), in particular, are known carriers of the virus, although they don't appear to get any kind of disease symptoms from it. Various primate species also get the disease, and in some cases humans became infected from contact with ill or dead apes or monkeys.
Risks of infection with Ebola and other zoonoses from wildlife in the tropical forests are obviously linked with hunting and the bushmeat trade, which could be reined in more effi ciently. Recent research suggests, however, that deforestation also increases the risks. John Emmanuel Fa from Manchester Metropolitan University, UK, in association with the Centre for International Forest Research, demonstrated a statistical correlation between Ebola outbreaks and recent deforestation (Scientifi c Reports (2017) 7, 14291).
Studying satellite records of vegetation changes near to 27 areas where Ebola outbreaks happened compared with 280 other areas where there were none, the researchers found that the loss of dense forest cover was an important risk factor in Ebola outbreaks. While previous studies had also hinted at such a connection, the new work also adds a time dimension, suggesting that the risk is particularly high within two years of the deforestation.
The most plausible underlying reason would be that disease-carrying animals losing their habitat are more likely to come into contact with humans than those thriving in remote, untouched rainforests. "The important thing in our research is that we are moving towards developing an early-warning system," Fa said in a press statement. "This research is fundamental for us being able to pinpoint the areas where Ebola outbreaks might occur in the future."
It is also quite possible that the remaining areas of as yet untouched tropical forests may harbour further strains of Ebola or other zoonoses that could cause even more damage than the ones that have emerged so far.
In spite of the clear medical relevance, researchers are still unsure about why bats, in particular, appear to be harbouring Ebola virus without getting ill. Writing on the Scientifi c American blogs just after the epidemic, Anna Fagre from Colorado State University at Fort Collins, USA, listed three as yet unproven hypotheses that may explain the special status of the fl ying mammals.
Their very ability to fl y, as it increases the metabolic rate, could serve a similar disease-fi ghting function as fever does in humans, some researchers believe. It could help to keep infections down without resulting in obvious suffering. On the genome level, bats have lost a whole family of genes linked to the immune system and specifi cally to the recognition of viruses, which may be linked to the peaceful cohabitation with Ebola virus. Another peculiarity in the immune response of bats that was only discovered recently is the fact that their cytokine signalling -which in humans would signal acute infection -is permanently 'on' (Proc. Natl. Acad. Sci.
USA (2016) 113, [2696] [2697] [2698] [2699] [2700] [2701] . This may help to snuff out viral infections before they begin to cause disease symptoms.
As Fagre points out, research with live bats under controlled laboratory conditions is challenging, to the extent that the ultimate reason why they are such resilient carriers has remained elusive. However, lessons in resilience may also be available from human survivors of the epidemics.
Survivors
The West African Ebola epidemic produced more victims than all previous outbreaks combined. With a mortality under 50%, it also produced more Ebola survivors than existed before. There are important questions to be asked regarding how long the virus can remain present in certain bodily fl uids. The large number of recent survivors will help to answer these more thoroughly than was possible before.
The WHO has set up preliminary guidance specifying in particular that male survivors should have their semen tested monthly and strictly observe safe sex practices until they have tested negative at least twice. This is because the virus is known to persist in immune-privileged tissues, including the testicles. Persistence of viruses in reproductive tissues of female survivors is also a concern, especially if they R54 Current Biology 28, R51-R65, January 22, 2018 were pregnant or breastfeeding while being exposed to the virus.
The good news from studies of Ebola survivors is that immunity against the virus appears to be long-lasting, sometimes even lifelong. The fi rst documented epidemic in the Democratic Republic of the Congo (then known as Zaire) left only 38 survivors. Eleven years after the event, some of them were tested and found to still have an effi cient immune response against the virus. A recent study re-examined six survivors that had suffered a serologically confi rmed Ebola infection in 1976 as well as eight others who had had the characteristic symptoms but no defi nitive confi rmation. Using three independent measures of immune responsiveness to Ebola, Anne Rimoin from the University of California at Los Angeles, USA, and colleagues found that sera from some of the survivors still responded positively to all three challenges, and were still fully able to neutralise live viruses (J. Infect. Dis. (2017) DOI: https://doi.org/10.1093/infdis/jix584).
This fi nding confi rms the value of the blood transfusion treatment that has been used in some cases during the recent epidemic. It also raises hopes that immunological treatment options could be developed on the basis of the long-term immunity observed in survivors.
All in all, many valuable lessons have been learned from the recent epidemic, ranging from the challenges of quarantine procedures and effi cient healthcare provision in such a crisis, through to the value of ring vaccinations and other preventive measures. Education and awareness efforts have also been stepped up as knowledge of transmission routes is crucial for the success of quarantine measures.
To better avoid further surprise epidemics of zoonotic diseases, however, much better understanding of the disease mechanisms and their ecological background in wildlife will be necessary. Research is only beginning to answer these important questions, and the problem is that we don't know how much time we have until the next epidemic strikes. When I arrived in London in 1968, I was 30 years old. I had done no laboratory science and I knew almost no immunology. NIMR was buzzing with outstanding immunologists, making it a perfect place to learn. Av suggested that I test whether an antigen on the surface of mouse thymocytes called theta (now called Thy1) could serve as a marker for peripheral T lymphocytes in mice. I showed that it could, which then allowed me and my colleagues to show that surface immunoglobulin could serve as a marker for B lymphocytes. Armed with these cell-surface markers, we were able to study the properties, functions, and development of both classes of mouse lymphocytes. Because Av declined to put his name on any of my papers, I became a well-known immunologist in my fi rst two years in science. When Av accepted a professorship at UCL in 1971, he invited me to move with him. Until that moment, I considered myself a clinical neurologist, but I quickly realised I should give up medicine, stay in the UK, and become a full-time scientist.
Do you think there is a cultural difference between working as a scientist in the UK compared with the US? Having only worked in science in the UK, I am not well placed to answer that. My impression, however, is that -in my day, at least -curiosity was the main driver of scientifi c discovery in Britain, whereas in the US competition seemed to have a bigger role: American scientists appeared to spend more time looking over their shoulder at their competitors than did British scientists. Science everywhere, however, is becoming more competitive, but I suspect that these differences persist even today. When you [Jordan] were a postdoc at UCSF, you commented that the American postdocs often worked nights and weekends, whereas you rarely did.
